Amikacin Indications in Pediatric Patients
Amikacin in children is primarily indicated as a second-line injectable aminoglycoside for drug-resistant tuberculosis and non-tuberculous mycobacterial infections, as well as for severe Gram-negative bacterial infections including neonatal sepsis, complicated intra-abdominal infections, and infections in immunocompromised hosts.
Primary Indications
Drug-Resistant Tuberculosis
Amikacin serves as a second-line injectable agent for pediatric patients with drug-resistant tuberculosis when the isolate demonstrates or is presumed to have susceptibility 1, 2, 1. The drug is particularly valuable because it maintains activity against most streptomycin-resistant strains and serum drug concentration measurements are readily available 2, 1.
Dosing for TB: 15-30 mg/kg/day (maximum 1 g/day) intramuscularly or intravenously as a single daily dose 1, 2, 1.
Non-Tuberculous Mycobacterial Disease
For NTM pulmonary disease, amikacin is used at 15-30 mg/kg daily or 15-30 mg/kg three times per week 3. Target peak levels are 25-35 mg/L for daily dosing or 65-80 mg/L for three-times-weekly dosing, with trough levels maintained below 5 mg/L 3.
Severe Bacterial Infections
Neonatal Sepsis: Amikacin combined with cloxacillin or cephalosporins (cefotaxime/ceftriaxone) is recommended as second-choice therapy for neonatal sepsis 4. The standard approach uses gentamicin first-line, reserving amikacin for resistant organisms or treatment failures.
Complicated Intra-Abdominal Infections: Amikacin at 15-22.5 mg/kg/day divided every 8-24 hours is an acceptable aminoglycoside option in pediatric patients with complicated intra-abdominal infections, typically combined with beta-lactam antibiotics 5.
Immunocompromised Hosts: Amikacin is extensively used for empiric therapy in febrile neutropenic episodes in pediatric cancer patients, typically combined with beta-lactam agents 6, 7.
Cystic Fibrosis: Amikacin is employed for pneumonitis in cystic fibrosis patients, though these patients often require higher doses due to increased clearance 6, 7.
Dosing Considerations
Standard Dosing
The FDA-approved dosing for children and older infants with normal renal function is 15 mg/kg/day divided into 2 or 3 equal doses (7.5 mg/kg q12h or 5 mg/kg q8h), with a maximum daily dose not exceeding 15 mg/kg/day 8.
Neonatal Dosing
For newborns, a loading dose of 10 mg/kg is recommended initially, followed by 7.5 mg/kg every 12 hours 8. However, recent evidence suggests a loading dose of 20 mg/kg may be necessary to achieve therapeutic peak concentrations between 30-40 mg/L 9.
Once-Daily Dosing
Once-daily dosing at 15 mg/kg is well-tolerated in pediatric patients, though individualized dosage adjustments are frequently necessary—required in 19 of 35 children in one study to achieve target peak concentrations 9.
Critical Monitoring Requirements
Therapeutic Drug Monitoring
Peak concentrations should be measured 30-90 minutes after injection and maintained at 30-40 mg/L for optimal efficacy while avoiding levels above 35 mcg/mL 8, 9. Trough concentrations (just prior to next dose) should remain below 10 mcg/mL to minimize toxicity 8.
Initial serum monitoring is essential in children due to wide interpatient variability in pharmacokinetics 9, 10, 11. Mean volume of distribution is approximately 0.59 L/kg and clearance 0.08 L/kg/h in critically ill children, though these parameters show large interindividual variations 11.
Safety Monitoring
Baseline assessments must include audiogram, vestibular testing, Romberg testing, and serum creatinine 1, 2. During therapy, assess renal function and question regarding auditory or vestibular symptoms monthly 1, 2. Repeat audiogram and vestibular testing if symptoms of eighth nerve toxicity develop 1.
For NTM treatment, monitor renal function twice weekly during month 1, weekly during month 2, then fortnightly to end of treatment 3.
Important Safety Considerations
Contraindications and Precautions
Amikacin is contraindicated in pregnancy due to risk of fetal nephrotoxicity and congenital hearing loss 1.
Toxicity Profile
Ototoxicity: Amikacin causes primarily auditory toxicity (deafness) with less vestibular dysfunction than streptomycin 1. High-frequency hearing loss occurred in 24% of patients in one report, with higher rates in those receiving longer treatment or higher doses 1.
Nephrotoxicity: Amikacin may be more nephrotoxic than streptomycin. Renal impairment was seen in 8.7% of patients, with higher frequency in those with initially elevated creatinine, larger total doses, or concurrent nephrotoxic agents 1, 2. However, pediatric studies have shown no nephrotoxicity when properly dosed and monitored 9, 12.
Renal Impairment Adjustments
In patients with renal insufficiency, reduce dosing frequency to 2-3 times per week but maintain the dose at 12-15 mg/kg to preserve concentration-dependent bactericidal effect 1, 2, 8. Administer after dialysis to facilitate directly observed therapy and avoid premature drug removal 1.
Clinical Efficacy
Amikacin achieved 82% complete cure rate and 10% partial cure rate across 66 pediatric patients with various Gram-negative infections 13. In urinary and gastrointestinal tract infections, it achieved 95% complete or partial cure rates 13. The drug has been used successfully as single-dose therapy for urinary tract infections 6.
Common Pitfalls
Inadequate early target attainment is frequent with standard dosing—23.3% of peak and 7.6% of trough values fell outside therapeutic targets in critically ill children 11. Critically ill pediatric patients demonstrate expanded volume of distribution and increased clearance, contributing to inadequate exposure under standard dosing 11.
Disease-specific alterations: Burn, cystic fibrosis, and oncology populations consistently demonstrate higher clearance and/or volume of distribution, often requiring higher doses for pharmacodynamic target attainment 10.